Protagonist Therapeutics Announces Investor Event Focused on Polycythemia Vera and Rusfertide

Protagonist Therapeutics will host an investor event on February 6, 2025 in New York. This hybrid event will feature insights from leading medical experts Dr. Andrew Kuykendall and Dr. Joseph Michael Scandura on the treatment landscape for polycythemia vera (PV), a rare chronic blood disorder. The discussion will include the potential role of Rusfertide, a hepcidin mimetic.

The event will also cover updates from Phase 2 studies PACIFIC and REVIVE, and the design of the Phase 3 VERIFY study. Results from VERIFY are anticipated in March 2025. Company management will discuss Rusfertide's commercial potential.

Following the presentations, there will be a live Q&A session. For in-person attendees, an informal lunch will provide additional engagement opportunities.